204 related articles for article (PubMed ID: 12940775)
1. The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2.
Attanoos RL; Griffin A; Gibbs AR
Histopathology; 2003 Sep; 43(3):231-8. PubMed ID: 12940775
[TBL] [Abstract][Full Text] [Related]
2. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis.
Cury PM; Butcher DN; Corrin B; Nicholson AG
J Pathol; 1999 Oct; 189(2):251-7. PubMed ID: 10547583
[TBL] [Abstract][Full Text] [Related]
3. The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions.
Hasteh F; Lin GY; Weidner N; Michael CW
Cancer Cytopathol; 2010 Apr; 118(2):90-6. PubMed ID: 20209622
[TBL] [Abstract][Full Text] [Related]
4. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
[TBL] [Abstract][Full Text] [Related]
5. Practical utility of insulin-like growth factor II mRNA-binding protein 3, glucose transporter 1, and epithelial membrane antigen for distinguishing malignant mesotheliomas from benign mesothelial proliferations.
Chang S; Oh MH; Ji SY; Han J; Kim TJ; Eom M; Kwon KY; Ha SY; Choi YD; Lee CH; Lee Y; Jung SH
Pathol Int; 2014 Dec; 64(12):607-12. PubMed ID: 25376377
[TBL] [Abstract][Full Text] [Related]
6. Immunoreactivity for the beta chain of the platelet-derived growth factor receptor in malignant mesothelioma and non-neoplastic mesothelium.
Ramael M; Buysse C; van den Bossche J; Segers K; van Marck E
J Pathol; 1992 May; 167(1):1-4. PubMed ID: 1320670
[TBL] [Abstract][Full Text] [Related]
7. New Markers for Separating Benign From Malignant Mesothelial Proliferations: Are We There Yet?
Churg A; Sheffield BS; Galateau-Salle F
Arch Pathol Lab Med; 2016 Apr; 140(4):318-21. PubMed ID: 26288396
[TBL] [Abstract][Full Text] [Related]
8. The role of desmin and N-cadherin in effusion cytology: a comparative study using established markers of mesothelial and epithelial cells.
Davidson B; Nielsen S; Christensen J; Asschenfeldt P; Berner A; Risberg B; Johansen P
Am J Surg Pathol; 2001 Nov; 25(11):1405-12. PubMed ID: 11684957
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic value of BRCA1-associated protein-1, glucose transporter-1 and desmin expression in the discrimination between reactive mesothelial proliferation and malignant mesothelioma in tissues and effusions.
Önder S; Özogul E; Koksal D; Sarinc Ulasli S; Firat P; Emri S
Cytopathology; 2019 Nov; 30(6):592-600. PubMed ID: 31165505
[TBL] [Abstract][Full Text] [Related]
10. p53 immunostaining in the distinction between benign and malignant mesothelial proliferations using formalin-fixed paraffin sections.
Mayall FG; Goddard H; Gibbs AR
J Pathol; 1992 Dec; 168(4):377-81. PubMed ID: 1484319
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of thirteen antibodies.
Roberts F; Harper CM; Downie I; Burnett RA
Am J Clin Pathol; 2001 Aug; 116(2):253-62. PubMed ID: 11488073
[TBL] [Abstract][Full Text] [Related]
12. Comparative immunohistochemical analysis of IMP3, GLUT1, EMA, CD146, and desmin for distinguishing malignant mesothelioma from reactive mesothelial cells.
Minato H; Kurose N; Fukushima M; Nojima T; Usuda K; Sagawa M; Sakuma T; Ooi A; Matsumoto I; Oda M; Arano Y; Shimizu J
Am J Clin Pathol; 2014 Jan; 141(1):85-93. PubMed ID: 24343741
[TBL] [Abstract][Full Text] [Related]
13. Expression of platelet-derived growth factor (PDGF) and PDGF receptors in human malignant mesothelioma in vitro and in vivo.
Langerak AW; De Laat PA; Van Der Linden-Van Beurden CA; Delahaye M; Van Der Kwast TH; Hoogsteden HC; Benner R; Versnel MA
J Pathol; 1996 Feb; 178(2):151-60. PubMed ID: 8683381
[TBL] [Abstract][Full Text] [Related]
14. Distinguishing benign from malignant mesothelial cells in effusions by Glut-1, EMA, and Desmin expression: an evidence-based approach.
Kuperman M; Florence RR; Pantanowitz L; Visintainer PF; Cibas ES; Otis CN
Diagn Cytopathol; 2013 Feb; 41(2):131-40. PubMed ID: 23002041
[TBL] [Abstract][Full Text] [Related]
15. The use of epithelial membrane antigen and silver-stained nucleolar organizer regions testing in the differential diagnosis of mesothelioma from benign reactive mesothelioses.
Wolanski KD; Whitaker D; Shilkin KB; Henderson DW
Cancer; 1998 Feb; 82(3):583-90. PubMed ID: 9452278
[TBL] [Abstract][Full Text] [Related]
16. CD44H expression in reactive mesothelium, pleural mesothelioma and pulmonary adenocarcinoma.
Attanoos RL; Webb R; Gibbs AR
Histopathology; 1997 Mar; 30(3):260-3. PubMed ID: 9088956
[TBL] [Abstract][Full Text] [Related]
17. Immunoreactivity for p53 protein in malignant mesothelioma and non-neoplastic mesothelium.
Ramael M; Lemmens G; Eerdekens C; Buysse C; Deblier I; Jacobs W; van Marck E
J Pathol; 1992 Dec; 168(4):371-5. PubMed ID: 1484318
[TBL] [Abstract][Full Text] [Related]
18. Immunoreactivity for c-fos and c-myc protein with the monoclonal antibodies 14E10 and 6E10 in malignant mesothelioma and non-neoplastic mesothelium of the pleura.
Ramael M; Van den Bossche J; Buysse C; Deblier I; Segers K; Van Marck E
Histol Histopathol; 1995 Jul; 10(3):639-43. PubMed ID: 7579812
[TBL] [Abstract][Full Text] [Related]
19. Keratin and epithelial membrane antigen immunoreactivity in nonneoplastic fibrous pleural lesions: implications for the diagnosis of desmoplastic mesothelioma.
Epstein JI; Budin RE
Hum Pathol; 1986 May; 17(5):514-9. PubMed ID: 2422109
[TBL] [Abstract][Full Text] [Related]
20. p53 expression is common in malignant mesothelioma.
Kafiri G; Thomas DM; Shepherd NA; Krausz T; Lane DP; Hall PA
Histopathology; 1992 Oct; 21(4):331-4. PubMed ID: 1398535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
